Looking again at the patent materials and having an interest particularly in their discovery of INH as an antichlamydial agent I selected this excerpt because of it's importance in restoring immune system functioning in those of us who have been immuno-compromised by Cpn. My daughter, for example, with terrible CFS/FM, gets every virus which happens by and always gets a worse case of it. Prior to treatment, I also got colds frequently. Cpn infects macrophages and monocytes, rendering these infected immune cells less functional. If this is a predominant site of one's infection, then it stands to reason that your immune system sucks! Or, more accurately, is being sucked on... because Cpn functions parasitically by stealing the mitochondrial energy of the cells it infects. I have highlighted and underlined some critical ideas in this excerpt. Thanks to Chuck Stratton, et al for your brilliant and underappreciated discoveries:
Excerpt From: Stratton/Mitchell patent #6,756,369
Novel Antichlamydial Therapy Directed Toward the Replicating and Cryptic Stationary Phases of Chlamydia Infection
A unique class of antichlamydial agents that is effective against the replicating and cryptic stationary phases of Chlamydia (and possibly against some other stages of the cryptic phase) have been identified using the susceptibility tests described herein. This novel class of agents comprises ethambutol and isonicotinic acid congeners which include isoniazid (INH), isonicotinic acid (also known as niacin), nicotinic acid, pyrazinamide, ethionamide, and aconiazide; where INH is most preferred. Although these are currently considered effective only for mycobacterial infections, due in part to currently available [susceptability] susceptibility testing methodologies, it has been discovered that these agents, in combination with other antibiotics, are particularly effective against Chlamydia. It is believed that the isonicotinic acid congeners target the constitutive production of catalase and peroxidase, which is a characteristic of microorganisms, such as mycobacteria, that infect monocytes and macrophages. Chlamydia can also successfully infect monocytes and macrophages. Using INH to eradicate Chlamydia from macrophages and monocytes subsequently assists these cells in their role of fighting infection. However, these agents appear to be less effective, in vitro, against the cryptic phase. Thus, ethambutol, INH and other isonicotinic acid congeners ideally should be used in combination with agents that target other phases of the chlamydial life cycle. These isonicotinic acid congeners are nevertheless excellent agents for the long term therapy of chronic/systemic chlamydial infection generally, and in particular to chlamydial infection of endothelial and smooth muscle cells in human blood vessels. INH and its congeners can be used to clear infection from monocytes and/or macrophages. When monocytes and macrophages are infected by Chlamydia, they become debilitated and cannot properly or effectively fight infection. It is believed that, if the chlamydial infection, per se, is cleared from these cells, then the monocytes and macrophages can resume their critical roles fighting chlamydial or other infection(s). Thus, patient responsiveness to combination therapy can be optimized by the inclusion of isonicotinic acid congeners. Accordingly, one aspect of the invention provides a specific method for reempowering monocytes or macrophages that have been compromised by a Chlamydia infection and, in turn, comprise treating the infection in other sites (Ed. This is saying that clearing these immune cells of Cpn also frees them to help fight the infection at other sites in the body). Such compromised macrophages or monocytes can be activated by treating the chlamydial infection by contacting the infected macrophages and/or monocytes with an antichlamydial agent.